PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective

Li, HaiXia and Zheng, Chao and Han, Jinming and Zhu, Jie and Liu, Shan and Jin, Tao (2021) PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective. Frontiers in Cellular Neuroscience, 15. ISSN 1662-5102

[thumbnail of pubmed-zip/versions/1/package-entries/fncel-15-716747/fncel-15-716747.pdf] Text
pubmed-zip/versions/1/package-entries/fncel-15-716747/fncel-15-716747.pdf - Published Version

Download (1MB)

Abstract

The programmed cell death protein-1/programmed death ligand-1 (PD-1/PD-L1) axis is a widely studied immune checkpoint that modulates signaling pathways related to T cell activation. The use of PD-1/PD-L1 inhibitors is a promising immune therapy strategy for cancer patients. However, individuals treated with PD-1/PD-L1 inhibitors may develop immune-related adverse events due to excessive immune reactions. Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disease of the central nervous system. T cells and the PD-1/PD-L1 axis play vital roles in the pathogenesis of MS. A better understanding of the complex relationship between the PD-1/PD-L1 axis and T cells may extend our knowledge of the molecular mechanisms and therapeutic approaches for MS. In this review, we summarize the most recent findings regarding the role of the PD-1/PD-L1 axis in MS and discuss the potential therapeutic strategies to modulate the expression of PD-1/PD-L1 in MS.

Item Type: Article
Subjects: Eprint Open STM Press > Medical Science
Depositing User: Unnamed user with email admin@eprint.openstmpress.com
Date Deposited: 21 Apr 2023 08:10
Last Modified: 02 Nov 2023 06:21
URI: http://library.go4manusub.com/id/eprint/71

Actions (login required)

View Item
View Item